Regen BioPharma Reports Significant Equity Issuances for Debt Conversion and Capital Raise
RGBP sits 34% above its 52-week low of $0.004 on elevated volume (6.4× avg).
Summary
Regen BioPharma issued over 21 million common shares in January 2026, converting approximately $32,550 in convertible debt and raising $50,000 through a Regulation A offering.
Key Events · Financing and Capital Events · RGBP
-
Debt Conversion on January 15
The company issued 5,000,000 common shares to satisfy $19,550 of convertible indebtedness (principal and interest).
-
Additional Debt Conversion on January 29
An additional 5,302,732 common shares were issued to satisfy $13,000 of convertible indebtedness (principal and interest).
-
Regulation A Offering on January 30
Regen BioPharma issued 11,111,111 common shares for $50,000 in cash, as part of a Tier 2 Regulation A Offering.
-
Significant Dilution
These transactions collectively resulted in the issuance of 21,413,843 new common shares, representing a substantial increase in the outstanding share count.
Analysis · RGBP · Life Sciences
This 8-K details several equity issuances in January 2026, resulting in substantial dilution for existing shareholders. The company converted approximately $32,550 of convertible debt into common shares and raised an additional $50,000 through a Tier 2 Regulation A offering. While these transactions provide some capital and reduce debt, the issuance of over 21 million shares represents a significant increase in the outstanding share count, impacting per-share value. This follows the Regulation A offering filed on January 8, 2026, indicating the company is actively seeking to raise capital.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RGBP was trading at $0.01 on OTC in the Life Sciences sector, with a market capitalization of approximately $551.1K. The 52-week trading range was $0.00 to $0.12. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.